OR-RADISYS
25.2.2022 18:02:10 CET | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today announced a showcase of its end-to-end open telecom and digital engagement portfolio at MWC Barcelona 2022 in Booth 5B81. Following the successful disaggregation of the flagship Media Server which is currently operating in over 200 networks, Radisys is extending the principles of disaggregation across both fixed and mobile broadband access offerings. Radisys’ Software-centric Network Functions, complemented by Open Hardware components, are now ready for operators to deploy to begin accruing the benefits of modern network architectures. Complementing these offerings, the focus on monetization leverages the power of computing-at-the-edge and offers new revenue opportunities.
Disaggregation of 5G and FTTX Access Networks
- Radisys will demonstrate 5GNR solutions enabled with its Release 16 compliant 5G software and systems integration capabilities. Attendees will learn how Radisys with its ecosystem partners is enabling a diverse customer base in the 5G space for CSPs, private networks and other market verticals. The 5G Innovation Showcase will include a 5G Small Cell demonstration with highly optimized architecture and low footprint and a network-in-a-box demonstration with 5G vRAN protocol software.
- Radisys will demonstrate its open, disaggregated, cloud native PON solution with the flexibility and scalability to transform FTTX networks. Attendees will see triple-play services over XGS-PON with Radisys’ Combo PON OLTs (simultaneous G-PON and XGS-PON support).
- Radisys is actively participating in the SD-RAN and VOLTHA demonstrations with ONF. Meet Radisys at the ONF Pavilion Hall 1 (Booth 1F66).
Broadband-everywhere
- Radisys will demonstrate the realization of true, converged broadband-everywhere networks powered by software-defined, disaggregated, Open RAN leveraging FTTX-based xHaul transport supported by automation, analytics monetization, and guaranteed assurance of service.
- Radisys will showcase its complete network lifecycle services – consult, design, build, integrate, operate, and optimize – across all of the network domains of today’s digital networks including the RAN, Optical/IP Transport, Core and Enterprise networks.
Monetization
- Radisys’ Smart Living Demonstration is made possible by Radisys’ Reach Smart Home that enables broadband service providers to increase customer stickiness and revenue by bundling smart home services with broadband plans. Use cases include comfort living, home security, safety and energy management. Radisys’ Smart Home Operator Dashboard brings insightful business KPIs for monetizing new services.
-
Radisys’ Digital Engagement showcase will highlight the video analytics capabilities of its Engage Platform, including mask detection and social distancing. Service providers can use these analytics to build specific applications such as biometric authentication and COVID policy enforcement.
- Attendees will have a personalized interaction with Radisys’ Engage Video Assistant (EVA) – the world’s first three-in-one AI-based video bot.
- Radisys will feature its newly launched Engage Digital Platform (EDP), a flexible, reliable and low code/no code Communications Platform-as-a-Service (CPaaS). Radisys will demonstrate the ease of use of the EDP Portal where admins and developers can create new services almost instantaneously via a drag and drop menu.
Leadership Presence
- Radisys and global service providers Deutsche Telekom and Reliance Jio will share their joint vision on disaggregated access during an interactive panel discussion taking place Tuesday, March 1 at 15:10-15:25 CET on the DT booth stage, Booth 3M31.
- Radisys is sponsoring the Open RAN Summit at MWC. Ganesh Shenbagaraman, head of integrated products and ecosystems, will participate on a panel discussion on “Open RAN Opportunity Use Cases” on March 2 from 2:30pm-3:30pm in CC3.13 Fira Gran Via.
- Radisys’ head of Mobility Software and Services, Munish Chhabra will participate in Xilinx’s 5G Leadership Power Hour Theater Session on March 2 from 9:30am-11:00am at the CET Theater 2 in Hall 7.
“Our theme for MWC is ‘Connectivity Reimagined, Experience Reimagined, Telco Reimagined’ and we are showing service provider and enterprise customers how our solutions can aid their network and business transformation with open platforms and architectures, and new innovative services and digital engagement solutions to reimagine their role as true digital engagement providers,” said Natasha Tamaskar, head of Global Marketing, Business Strategy and Digital Endpoints Business, Radisys. “Unlike other modern OEMs in the market, Radisys has a unique position as our portfolio covers both fixed and mobile access and leverages the global footprint of our media platform complemented by digital endpoints and services. Our solutions enable greater service opportunities and enhanced digital experiences for customers across the globe.”
To meet with Radisys’ experts at MWC Barcelona and learn more about innovations in Open RAN, broadband, and digital engagement, contact open@radisys.com .
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications’ and content providers’ complex deployment challenges. For more information, visit www.Radisys.com .
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220225005400/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
